Sancycline is a semisynthetic tetracycline antibiotic that is more active than tetracycline against 339 strains of anaerobic bacteria (average MIC90s = 1 and 32 μg/ml, respectively). Sancycline is active against tetracycline-resistant E. coli, S. aureus, and E. faecalis strains with MICs ranging from 0.06 to 1 μg/ml. In vivo, sancycline is active against S. aureus in mice with ED50 values of 0.46 and 0.6 mg/kg for intravenous and subcutaneous administration, respectively.
Sancycline is a rare semi-synthetic tetracycline prepared by hydrogenolysis of the chloro and benzylic hydroxy moieties of declomycin, first reported in 1962. As the simplest of the early tetracyclines, sancycline was the first to be totally synthesised by Conover and co-workers. Like other tetracyclines, sancycline acts by reversibly binding to the 30S ribosomal subunit and inhibiting protein translation by blocking entry of aminoacyl-tRNA into the ribosome A site.
A semi-synthetic antibiotic related to tetracycline
Sancycline is a tetracycline bacteriostatic antibiotic which also binds to the Tet repressor protein (TetR).
ChEBI: Sancycline is a member of tetracyclines.
